Jess Jankowski - 31 Dec 2024 Form 4 Insider Report for NANOPHASE TECHNOLOGIES Corp (SLSN)

Signature
/s/ Jess Jankowski
Issuer symbol
SLSN
Transactions as of
31 Dec 2024
Net transactions value
+$54,900
Form type
4
Filing time
13 Jan 2025, 17:29:23 UTC
Previous filing
25 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding NANX Common Stock 1,000 31 Dec 2024 Spouse's IRA
holding NANX Common Stock 207,450 31 Dec 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NANX Common Stock (right to purchase) Award $54,900 +22,500 $2.44 22,500 31 Dec 2024 Common Stock 22,500 $2.44 Direct F1
holding NANX Common Stock (right to purchase) 69,000 31 Dec 2024 Common Stock 69,000 $0.4200 Direct F1
holding NANX Common Stock (right to purchase) 81,000 31 Dec 2024 Common Stock 81,000 $0.6800 Direct F1
holding NANX Common Stock (right to purchase) 90,000 31 Dec 2024 Common Stock 90,000 $0.8200 Direct F1
holding NANX Common Stock (right to purchase) 16,500 31 Dec 2024 Common Stock 16,500 $0.5100 Direct F1
holding NANX Common Stock (right to purchase) 90,000 31 Dec 2024 Common Stock 90,000 $0.4500 Direct F1
holding NANX Common Stock (right to purchase) 90,000 31 Dec 2024 Common Stock 90,000 $4.17 Direct F1
holding NANX Common Stock (right to purchase) 72,000 31 Dec 2024 Common Stock 72,000 $1.16 Direct F1
holding NANX Common Stock (right to purchase) 12,600 31 Dec 2024 Common Stock 12,600 $0.6100 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.

Remarks:

This report is being filed late due to an administrative error on the part of the Company. Mr. Jankowski received this grant of stock options as part of the Company's annual equity compensation practices.